Kenvue Inc. (KVUE) — ESG & Values Scores

Environment story

Kenvue's environmental posture is significantly weakened by undisclosed Scope 1, 2, and 3 emissions data and the absence of a credible net-zero target year. The 10-K acknowledges climate change as a risk factor but provides no quantitative emissions baselines, reduction pathways, or sustainability commitments. The company faces tariff-driven supply chain cost inflation (~$130M annualized) and acknowledges input cost volatility from climate-sensitive raw materials (pulp, oils, agrochemicals), yet does not articulate decarbonization investments. A pending acetaminophen label change may reduce product sales but does not constitute environmental progress. No evidence of renewable energy procurement, Scope 3 mitigation, or science-based targets. The company does not publicly disclose sustainability or ESG reporting.

Criticisms on file

No disclosed emissions inventory (Scope 1, 2, 3), net-zero target, or sustainability commitments despite being a $15.1B consumer health company.
Source: KVUE 10-K 2025, Item 1A Risk Factors; MD&A contains no sustainability section.
Acetaminophen regulatory risk: September 2025 FDA allegation of in utero neurodevelopmental harm (autism, ADHD); pending label changes and citizen petitions could depress Tylenol sales.
Source: KVUE 10-K 2025, MD&A—Acetaminophen Regulatory Developments; Note 17 Commitments and Contingencies.
Tariff exposure of ~$130M annualized (2025) due to U.S. trade policy; company mitigating via internal actions but supply chain carbon intensity not addressed.
Source: KVUE 10-K 2025, MD&A—Macroeconomic Developments.

Disclosed initiatives

Supply Chain Optimization

Company reports supply chain optimization initiatives and benefits realization, with annualized gross cost savings exceeding $350 million as of fiscal year 2025 end.

Cost savings may indirectly reduce operational footprint, but no explicit decarbonization or emissions reduction metric disclosed.

Social story

Kenvue discloses limited social data. No CEO-to-worker pay ratio provided; workforce diversity metrics absent from 10-K. The company acknowledges dependence on attracting/retaining skilled employees and highlights brand reputation tied to consumer/employee representation, but no formal diversity targets, pay equity commitments, or supplier diversity programs are disclosed. Supply chain includes reliance on third-party manufacturers and suppliers globally, with legacy J&J contracts creating ongoing compliance risks. No documented labor disputes, union-suppression activity, or NLRB complaints mentioned in 10-K. However, absence of positive labor standing disclosures (e.g., neutrality agreements, living wage commitments) and no modern slavery statement or conflict minerals policy evident. Separation from J&J and restructuring (2024 Multi-Year Initiative with significant workforce reductions) signal workforce instability.

Criticisms on file

No disclosed CEO-to-median-worker pay ratio, workforce diversity metrics (gender, race/ethnicity), or pay equity analysis in 10-K.
Source: KVUE 10-K 2025; fact_sheet request yields null for all DEI workforce metrics.
Significant workforce reductions via 2024 Multi-Year Restructuring Initiative create potential employee morale and retention risks acknowledged in 10-K.
Source: KVUE 10-K 2025, MD&A—Restructuring; Note 19 Restructuring Expenses.
Supply chain reliance on third-party manufacturers globally with legacy J&J contracts; company acknowledges 'lesser degree of control' over compliance, quality, and cybersecurity.
Source: KVUE 10-K 2025, Item 1A Risk Factors—Reliance on Third Parties; Note 12 Relationship with J&J.
No disclosed modern slavery statement, forced labor policy, conflict minerals commitment, or supply-chain human rights audits.
Source: KVUE 10-K 2025; absence of disclosures in MD&A or Risk Factors.

Disclosed initiatives

2024 Multi-Year Restructuring Initiative

Approved May 6, 2024; includes global workforce reductions, management structure changes, and centralized shared-service functions in lower-cost locations. Substantially completed by fiscal year 2025 end with $556M in pre-tax restructuring charges.

Cost savings of >$350M annualized achieved, but significant workforce disruption and potential labor relations risk.
Brand Representation & Consumer Alignment

Company strategy emphasizes hiring employees who 'represent our consumers' and states business depends on ability to attract talented employees who reflect consumers.

Stated intention toward diversity, but no quantified targets, measurement, or accountability disclosed.

Governance story

Kenvue exhibits mixed governance: the company is a recently independent public entity (May 2023 IPO from J&J spin-off) with standard single-class share structure and no dual-class voting identified. Board independence percentage not disclosed in 10-K examined. The company faces significant governance disruption from the Proposed Transaction with Kimberly-Clark Corporation (announced November 2025), requiring shareholder approval and regulatory clearance; merger-related litigation has been filed by shareholders. No explicit lobbying expenditure disclosure or anti-climate lobbying identified, but company acknowledges broad regulatory compliance obligations (climate, trade, tariffs, AI regulation). No antitrust proceedings, consumer-safety fines, or SEC consent decrees mentioned; however, acetaminophen litigation risk is material (pending label change, citizen petitions). Separation-related costs and Proposed Transaction costs represent significant non-operating governance burdens. No evidence of shareholder activism campaigns suppressed via litigation.

Criticisms on file

Proposed Transaction with Kimberly-Clark litigation: shareholder lawsuits filed challenging merger; Merger Agreement imposes 'no shop' covenants restricting strategic alternatives.
Source: KVUE 10-K 2025, Item 1A Risk Factors—Litigation against us or K-C; MD&A—Strategic Review and Proposed Transaction.
Merger Agreement restricts business conduct, acquisitions, and divestitures prior to closing; could impair standalone strategic execution if deal delayed/terminated.
Source: KVUE 10-K 2025, Item 1A Risk Factors—Merger Agreement Restrictions.
No disclosed board independence percentage; governance structure post-J&J separation not fully transparent regarding independent director composition.
Source: KVUE 10-K 2025; proxy statement (DEF 14A) not provided in source documents.
Acetaminophen regulatory action: FDA alleges in utero neurological harm; third-party citizen petitions filed September/November 2025; label change pending; litigation risk material (Note 17 references pending acetaminophen litigation).
Source: KVUE 10-K 2025, MD&A—Acetaminophen Regulatory Developments; Note 17 Commitments and Contingencies.

Disclosed initiatives

Strategic Review Committee & Proposed Merger with Kimberly-Clark

Board initiated comprehensive strategic review in July 2025; November 2, 2025 approved Merger Agreement with K-C. Transaction announced with 0.14625 K-C shares + $3.50 cash per KVUE share; expected closing H2 2026; shareholders approved January 29, 2026; HSR waiting period expired February 4, 2026.

Significant governance transition and shareholder voting dilution (KVUE shareholders own ~46% of combined entity post-close). Material transaction costs ($25M disclosed for fiscal 2025) and litigation risk from shareholder challenges.
Cybersecurity Risk Management Framework

Company discloses cybersecurity risk governance in Item 1C of 10-K; acknowledges Technology Systems managed by third parties and AI-driven threat escalation.

Governance framework acknowledged but no board oversight metrics or incident disclosure provided; to date no material cybersecurity incidents reported.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Kenvue Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Kenvue Inc. in the app for interactive charts and portfolio building.

More in Consumer Staples

Walmart Inc. (WMT) Costco Wholesale Corporation (COST) The Coca-Cola Company (KO) The Procter & Gamble Company (PG) Philip Morris International Inc. (PM) PepsiCo Inc. (PEP)